Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Gilead's CEO Says New Hepatitis C Drug Attracts Payers

Editor's pick
Bloomberg Businessweek
13 February 2014
New & experimental hepatitis C treatment

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

Editor's pick
Gilead press release
11 February 2014
New & experimental hepatitis C treatment

New hepatitis C pill lifts Gilead's 4Q sales

Editor's pick
Bloomberg Businessweek
7 February 2014
New & experimental hepatitis C treatment

Gilead to license hepatitis C drug to lower-cost manufacturers in India

Editor's pick
Reuters
6 February 2014
New & experimental hepatitis C treatment

Gilead, local generic players in talks to bring hepatitis C drug into India

Editor's pick
The Hindu
4 February 2014
New & experimental hepatitis C treatment

Abbvie Strong Hep C Drug Data and the Looming Battle With Gilead Sciences

Editor's pick
The Street
3 February 2014
New & experimental hepatitis C treatment

AbbVie Completes Largest Phase III Program of an All-Oral, Interferon-Free Therapy for the Treatment of Hepatitis C Genotype 1

Editor's pick
AbbVie press release
31 January 2014
Access to healthcare

At $84000 Gilead Hepatitis C Drug Sets Off Payer Revolt

Editor's pick
Bloomberg
27 January 2014
New & experimental hepatitis C treatment

Only just the beginning of the end of hepatitis C

Editor's pick
The Lancet (editorial)
26 January 2014
New & experimental hepatitis C treatment

Hep C drug deleobuvir pulled from clinical study, citing high rate of early discontinuations

Editor's pick
Project Inform
21 January 2014
New & experimental hepatitis C treatment

European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

Editor's pick
Gilead press release
17 January 2014
New & experimental hepatitis C treatment

Bristol-Myers Ties Hepatitis C Success to Gilead’s Pill

Editor's pick
Bloomberg
14 January 2014
New & experimental hepatitis C treatment

What Is a Hepatitis C Drug Worth?

Editor's pick
Roll Call
14 January 2014
New & experimental hepatitis C treatment

Achillion Reports HCV Pipeline Progress and Outlines 2014 HCV Milestones

Editor's pick
Achillion press release
14 January 2014
New & experimental hepatitis C treatment

Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

Editor's pick
Vertex press release
9 January 2014
New & experimental hepatitis C treatment

Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency

Editor's pick
Bristol-Myers Squibb press release
8 January 2014
New & experimental hepatitis C treatment

$1000 Pill For Hepatitis C Spurs Debate Over Drug Prices

Editor's pick
NPR (blog)
6 January 2014
Hepatitis C treatment

Gilead Sciences, Inc. (GILD): Gilead Seeks To Expand Its Blockbuster Hepatitis Platforms In 2014

Editor's pick
Seeking Alpha
3 January 2014
New & experimental hepatitis C treatment

Stellar hepatitis C data puts Gilead farther ahead of pack

Editor's pick
Reuters
24 December 2013
Access to healthcare

Life-saving hepatitis C drug approved, but cost is high

Editor's pick
IRIN Plus News
24 December 2013
Access to healthcare

Egyptians hold their breath as new Hepatitis C drugs promise cure

Editor's pick
Ahram Online
24 December 2013
New & experimental hepatitis C treatment

Gilead to seek okay for combo hepatitis C pill in first quarter

Editor's pick
Reuters
18 December 2013
New & experimental hepatitis C treatment

Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients

Editor's pick
Gilead press release
18 December 2013
Access to healthcare

How patent rules could keep new hepatitis C drug from saving 'millions of lives'

Editor's pick
Global Post
18 December 2013